The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
 
Barbara Pistilli
Consulting or Advisory Role - Myriad Genetics; Novartis; Pierre Fabre; Puma Biotechnology
Research Funding - Merus (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Novartis; Pfizer
 
Hans Wildiers
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); IQvia (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sirtex Medical (Inst)
Research Funding - Roche (Inst)
Expert Testimony - Abbvie; Ariez Pharma; Ariez Pharma; Biocartis; DNA Prime; Lilly; Novartis; The Planning Shop; TRM Oncology
Travel, Accommodations, Expenses - Congress Care; DNA Prime; Global Teamwork; Pfizer; Puma Biotechnology; Roche; Roche (Inst); TRM Oncology
 
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Ana Alexandra Ferreira
No Relationships to Disclose
 
Florence Dalenc
Travel, Accommodations, Expenses - Pfizer; Roche
 
Maria Vidal
Consulting or Advisory Role - Novartis/Pfizer
Speakers' Bureau - Eisai; Novartis/Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Pfizer
 
Joaquín Gavilá
No Relationships to Disclose
 
Anthony Goncalves
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Lilly (Inst); Merus (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Roche (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche/Genentech
 
Carmen Murias
No Relationships to Disclose
 
Marie-Ange Mouret-Reynier
No Relationships to Disclose
 
Jean-Luc Re Canon
No Relationships to Disclose
 
Fernando Bazan
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Sylvain Ladoire
No Relationships to Disclose
 
L. Andres Sirulnik
Employment - Merus NV
Stock and Other Ownership Interests - Merus NV
 
Mohamed Bekradda
No Relationships to Disclose
 
Kees Bol
Employment - Merus NV
 
Viktoriya Stalbovskaya
Employment - Merus NV
 
Anastasia Murat
Employment - Merus NV
 
Jim Ford
Employment - Merus NV
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer
Speakers' Bureau - Amgen; Amgen; AstraZeneca; Novartis; Pfizer
Research Funding - Menarini Silicon Biosystems (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - MSI and ESR1 detection by ddPCR (patents pending) (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Menarini Silicon Biosystems; Pfizer; Roche